The Europe TB diagnostics market was valued at USD 410.00 million in 2025 and is projected to grow from USD 431.94 million in 2026 to reach USD 655.38 million by 2034, exhibiting a CAGR of 5.35% during the forecast period 2026-2034.
Tuberculosis (TB) is an infectious illness caused by Mycobacterium tuberculosis bacteria (MTB). Tuberculosis is most associated with the lungs, although it may also affect other regions of the body. Most infections are asymptomatic, which is known as latent TB. Roughly 10% of latent infections progress to active illness, which kills about half of the individuals afflicted if left untreated. A persistent cough with bloody sputum, fever, night sweats, and weight loss are all hallmark indications of active tuberculosis. Weight loss gave rise to the historical phrase "consumption." Other organ infections can generate a variety of symptoms.
Active TB symptoms include a chronic cough with bloody mucus, fever, night sweats, and weight loss. The most frequent European TB diagnostic procedure is a skin test; however, blood tests are becoming more widespread
The bacteria Mycobacterium tuberculosis causes tuberculosis, which is an infectious illness (MTB). Tuberculosis usually affects the lungs, but it may also affect other regions of the body. Most TB infections are asymptomatic, known as latent tuberculosis. If left untreated, around 10% of latent infections progress to active disease, killing half of the affected people.
Although there has been significant improvement in tuberculosis diagnosis and treatment over the last decade, tuberculosis (TB) remains a public health problem throughout the European region. Nations outside the European Union (EU) and Europe Economic Area (EEA) continue to have high rates of tuberculosis (TB) and multidrug-resistant (MDR) TB, whereas EU/EEA countries have a high number of TB cases among vulnerable populations, such as immigrants and prisoners. Men are more affected by tuberculosis than women, and there are larger gaps in case detection and reporting among men. Because of the high number of TB deaths in Europe, governments are taking steps and implementing standards in each country to enhance diagnosis and treatment procedures. Guidelines are mostly accessible in high-income nations that have developed LTBI (latent tuberculosis) screening programmes. According to the World Health Organization (WHO), 1.5 million people died from tuberculosis in 2018. (Including 251 000 people with HIV). TB is one of the top ten causes of death worldwide and the main cause of death from a single infectious agent (behind HIV/AIDS).
Download a Free Sample To learn more about this report,
Automated Nucleic Acid Amplification Testing
Automated nucleic acid amplification testing is becoming more important as European TB programs seek faster detection of TB and drug resistance with less manual laboratory work. The transition toward low- and moderate-complexity automated NAAT platforms supports decentralized testing and quicker reporting, with WHO reporting pooled sensitivity of 93.0% for TB detection for moderate-complexity automated NAATs. This shift expands the role of automated molecular diagnostics across European laboratories and supports faster treatment decisions.
Digital Integration of TB Laboratory Data
Digital integration is linking TB laboratory results with surveillance systems to improve data quality, reporting, and disease monitoring across Europe. The transition toward connected laboratory and surveillance platforms supports more consistent sharing of diagnostic information, while ECDC’s 2026 laboratory handbook highlights the need for robust laboratory data to support European surveillance systems. This integration enables health authorities to use diagnostic data more efficiently for europe-tb-diagnostics-market analysis and public-health response.
Adoption of Targeted Next-Generation Sequencing for Drug Resistance and Strengthening of Laboratory Quality and Accreditation Drive Market
Drug-resistant TB surveillance programs and reference laboratories need detailed resistance profiles to support treatment selection and epidemiological monitoring.Targeted next-generation sequencing can identify multiple resistance-associated mutations from TB samples, increasing demand for sequencing reagents, panels, and specialized laboratory services. European reference laboratories already use genome-sequencing approaches for TB molecular typing and resistance-related work, providing a practical application. Wider use of targeted sequencing can expand the diagnostic supply base beyond conventional resistance-testing methods.
TB laboratories and national reference laboratories require standardized procedures and quality systems to maintain reliable diagnostic results across Europe. ISO 15189 accreditation requires validated methods, staff competency, equipment control, internal audits, and continuous quality monitoring, increasing demand for quality-assurance services and diagnostic materials. ECDC's European Reference Laboratory Network for TB supports external quality-assessment programs and harmonization of laboratory methods across EU/EEA countries. Greater laboratory compliance can support demand for validated TB diagnostic systems, proficiency-testing materials, and laboratory quality-management solutions.
Budget Constraints in Public Healthcare Systems and Complex Regulatory Requirements for Diagnostic Devices Restrain Market Expansion
Budget constraints in public healthcare systems limit spending on advanced TB screening, molecular tests, laboratory equipment, and diagnostic programs.Restricted healthcare budgets can delay procurement and reduce the availability of newer diagnostic technologies across some healthcare facilities.This funding pressure can slow diagnostic capacity expansion and limit adoption of advanced TB diagnostics.
Complex regulatory requirements require diagnostic manufacturers to complete extensive validation, documentation, quality, and compliance procedures before market entry.These requirements increase development costs and extend the time needed to introduce new TB diagnostic devices.This regulatory burden can delay technology adoption and reduce the pace of product innovation in the market.
AI-Based Chest X-Ray Screening Solutions and Multiplex TB and Respiratory Infection Testing Offers Growth Opportunities
Public health programs, hospitals, and radiology providers are key users, as AI can support rapid TB screening and triage from chest X-rays. Diagnostic technology companies can generate revenue through AI software licensing, screening platforms, and integration services. Companies such as Qure.ai, Delft Imaging, and Lunit already offer AI-based TB chest X-ray solutions.
Hospitals, diagnostic laboratories, and respiratory-care providers are key users seeking broader testing from a single diagnostic workflow. Diagnostic manufacturers can create new revenue through multiplex assays that detect TB alongside other respiratory pathogens, expanding test menus and laboratory applications. The opportunity supports broader respiratory diagnostics beyond standalone TB testing, creating additional applications for assay developers. .
Competition from a Rapidly Expanding Diagnostic Pipeline and Procurement and Equipment Supply Delays Hinders Growth
The growing number of emerging TB diagnostic technologies increases competitive and development pressure on existing manufacturers. WHO reported almost 100 TB diagnostic products in development in August 2025, requiring companies to differentiate products through accuracy, speed, workflow, and accessibility. Frequent product innovation can shorten technology cycles and increase the need for continuous product development. Smaller diagnostic companies may find it difficult to maintain visibility and compete for healthcare procurement opportunities.
Laboratories face difficulties securing specialized equipment and maintaining reliable diagnostic supply chains, which can delay installation and expansion of testing capacity. ECDC reported equipment shortages and procurement problems affecting public-health laboratories in its 2025 assessment. Long procurement timelines can postpone the deployment of new diagnostic platforms and reduce testing capacity. Delays in obtaining essential components can also disrupt manufacturers' delivery schedules and customer expansion plans.
Nucleic Acid Testing (NAT) plays an important role in TB diagnostics because molecular tests provide rapid detection of TB and can identify drug resistance. Skin Test / Mantoux Test (TST) remains useful for identifying TB infection, particularly in screening and clinical assessment. Blood Test / Serology Test supports TB-related screening and diagnostic evaluation in appropriate clinical settings. SMEAR Microscopy remains an established method for detecting acid-fast bacilli in clinical specimens. Cultured-Based Tests support microbiological confirmation and drug-susceptibility testing through the growth of mycobacterium tuberculosis. Radiography tests assist clinicians in identifying lung abnormalities that may indicate TB and support further diagnostic evaluation. Others include specialized and emerging diagnostic methods that complement established TB testing approaches.
Request Customizationto receive a tailored report.
Hospitals and Diagnostic Laboratories represent an important end-user group because they provide established clinical and laboratory infrastructure for TB testing. Physician’s Office Laboratories support diagnostic evaluation closer to the point of patient consultation. Reference Laboratories play a key role in specialized testing, quality assurance, and standardized TB diagnostic services across Europe. Academics and Research Facilities contribute to the development, validation, and evaluation of new TB diagnostic technologies and testing methods.
Speak to an Analystto discuss market opportunities.
The Europe TB Diagnostics Market accounted for the largest regional share of 27.6% in 2025. The region maintained a significant position in the market, supported by continued demand for tuberculosis detection and diagnostic testing.
The UK is targeting a 90% reduction in TB incidence by 2035, requiring an average annual decline of 18.2% from 2025 onward, which supports continued demand for TB detection and diagnostic services Germany aims to reduce TB incidence to below 1 case per 100,000 population by 2035, requiring an annual incidence decline of at least 10%, supporting continued screening and diagnostic efforts .France WHO’s End TB Strategy targets a 90% reduction in TB incidence by 2035, with early diagnosis and universal drug-susceptibility testing identified as key interventions, providing a future policy driver for TB diagnostic services in France.
The Europe TB diagnostics market is moderately fragmented, with the market ecosystem comprising global diagnostic companies, molecular testing manufacturers, laboratory equipment providers, specialized tuberculosis diagnostic firms, clinical laboratories, and emerging biotechnology companies. The leading players in the Europe TB diagnostics market include Hoffmann-La Roche AG, bioMérieux SA, QIAGEN, Hain Lifescience, and Abbott Laboratories, with the five companies collectively accounting for approximately 20% of the global TB diagnostics market based on available company-level market-share data, reflecting their combined market share.
Established players compete mainly through diagnostic accuracy, test sensitivity and specificity, product reliability, regulatory approvals, broad distribution networks, laboratory integration, and technical support, while the market ecosystem supports a range of suppliers, technology providers, laboratories, and diagnostic companies. Emerging players compete through rapid testing technologies, portable diagnostic solutions, multiplex platforms, automation, cost efficiency, and innovative molecular detection methods.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Genome Editing Market Size, Share, Growth, Analysis, Report, 2034
Organ Preservation Market Size, Share, Growth, Analysis, Report, 2034
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com